AD Ports Group to boost Hayat Biotech’s global expansion with new MoU

AD Ports Group to boost Hayat Biotech’s global expansion with new MoU

AD Ports Group and UAE-based Hayat Biotech have signed a memorandum of understanding (MoU) to enable the latter to set up manufacturing centres around the globe and provide logistics solutions to serve its international markets. The agreement covers the shipping of strategic construction supplies, including containers, machinery, raw materials and equipment, to support the construction of Hayat Biotech’s global biopharmaceutical manufacturing facilities. The facilities – once complete – will produce a number of vital biopharmaceutical products, including the Hayat-Vax vaccine, the first indigenously produced Covid-19 vaccine in the UAE and Arab world. As part of the collaboration, the distribution will be handled by the HOPE Consortium, which is said to operate one of the largest and most complete end-to-end pharma supply chains today. Alongside the Department of Health – Abu Dhabi, Etihad Cargo, Maqta Gateway, Rafed, and SkyCell, AD Ports Group is one of the founding members of the HOPE Consortium, which is helping lead the distribution of Covid-19 vaccines to all parts of the globe. The partnership has handled over 250 million vaccine doses across 60 countries. Captain Mohamed Juma Al Shamisi, MD and group CEO of AD Ports Group, and chairman of the HOPE Consortium’s Executive Committee, said: